Related Experiment Video
Updated: Jun 4, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Negative patch test findings after initiation of upadacitinib: A case report
Meghan L McPhie1,2, Melanie D Pratt1,2, Mark G Kirchhof1,2
1Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Abstract:
Upadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis. The utility of Janus kinase inhibitors for the treatment of allergic contact dermatitis and the effect on patch testing results remains unclear. We present a case of a woman in her 30s with atopic dermatitis and allergic contact dermatitis who was patch test negative after initiating therapy with upadacitinib.
